Most Read Articles
Roshini Claire Anthony, 24 Nov 2016

Moderate doses of celecoxib are noninferior to naproxen or ibuprofen in terms of cardiovascular (CV) safety, according to results of the PRECISION* trial presented at the Scientific Sessions of the American Heart Association held recently in New Orleans, Louisiana, US.

Roshini Claire Anthony, 28 Feb 2017

Recent neuropathic pain management guidelines have highlighted specific drugs to be used as first, second, and third line treatment of neuropathic pain, according to a presentation at the 7th Association of South-East Asian Pain Societies Congress (ASEAPS 2017) held in Yangon, Myanmar.

Audrey Abella, 04 Apr 2017
Pregabalin did not significantly reduce symptoms of sciatica, including radiating posterolateral leg pain and back pain, compared with placebo, according to data from the PRECISE* trial.
06 Jan 2018
Celecoxib at approved dosages show similar or better cardiovascular, gastrointestinal, and renal safety profiles compared with ibuprofen and naproxen in the management of osteoarthritis and rheumatoid arthritis, a recent study has reported.

Post-marketing data reaffirm vedolizumab safety in real world

Pearl Toh
28 Jan 2019

The favourable safety profile of vedolizumab in patients with inflammatory bowel disease (IBD) persists even in real-world clinical practice, according to the first 4 years of post-marketing safety data reported at AIBD 2018.

“[Randomized trials] only included patients meeting eligibility criteria, who may not reflect real-world clinical practice,” the researchers stated. “The favourable safety profile of vedolizumab in Crohn’s disease [CD] and ulcerative colitis [UC] in the post-marketing setting is consistent with that established in clinical trials.”

Based on the manufacturer’s global safety database containing about 208,050 patient-years of vedolizumab exposure, 80,218 adverse events (AEs) were reported in 32,752 patients. Of these, 47 percent were detected in patients with CD and 43 percent were in UC; while another 10 percent were reported in patients receiving vedolizumab for off-label use. [AIBD 2018, abstract P014]   

The most commonly reported AEs were those involving the gastrointestinal (GI) system, as seen in 6,156 (16 percent) patients with CD and 5,701 (17 percent) patients with UC.

Malignancies occurred in 140 patients with CD and 123 patients with UC, with lower GI malignancies being the most common type (23 patients [16 percent] and 34 [27 percent], respectively).

One hundred and twelve patients with CD and 186 patients with UC had infusion-site reactions, whereas lupus-related AEs were reported in 10 and 9 patients, respectively.

There were 5,230 serious AEs in patients with CD and 3,580 in those with UC — the most frequent being events related to exacerbation of underlying disease (11 percent and 8 percent for CD and UC, respectively).  

“Most reported AEs with vedolizumab were non-serious, and frequencies of AEs of particular clinical interest appeared low,” said the researchers.

Infections were documented in 3,064 patients with CD and 2,812 with UC, of which 23 percent and 15 percent of the cases were serious. Ninety-five patients with CD and 193 patients with UC had opportunistic infections, of which one was a case of progressive multifocal leukoencephalopathy in a patient with CD who had untreated HIV and was taking long-term immunosuppressant with other agents.

The rates of infections of particular clinical significance were low: nine cases of histoplasmosis and two cases of nocardiosis were detected in patients with CD, and tuberculosis was observed in five patients with CD and 4 with UC.

In terms of pregnancy-related events, 46 percent of 652 women receiving vedolizumab experienced an AE, with the most commonly reported being spontaneous abortion (n=48). In addition, ten women reported congenital abnormalities.

“Of the patients with CD or UC reporting AEs, 74 percent continued vedolizumab treatment,” the researchers noted.

“Limitations of post-marketing safety reports … must be considered when interpreting these results,” they advised, pointing out that such limitations include incomplete data, increased reporting of serious AEs as opposed to non-serious AEs, and voluntary reporting, and cautioned against drawing any causal relationship between the medication and event from such reports.

 

 

 

  

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 24 Nov 2016

Moderate doses of celecoxib are noninferior to naproxen or ibuprofen in terms of cardiovascular (CV) safety, according to results of the PRECISION* trial presented at the Scientific Sessions of the American Heart Association held recently in New Orleans, Louisiana, US.

Roshini Claire Anthony, 28 Feb 2017

Recent neuropathic pain management guidelines have highlighted specific drugs to be used as first, second, and third line treatment of neuropathic pain, according to a presentation at the 7th Association of South-East Asian Pain Societies Congress (ASEAPS 2017) held in Yangon, Myanmar.

Audrey Abella, 04 Apr 2017
Pregabalin did not significantly reduce symptoms of sciatica, including radiating posterolateral leg pain and back pain, compared with placebo, according to data from the PRECISE* trial.
06 Jan 2018
Celecoxib at approved dosages show similar or better cardiovascular, gastrointestinal, and renal safety profiles compared with ibuprofen and naproxen in the management of osteoarthritis and rheumatoid arthritis, a recent study has reported.